Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach by Katsakiori, Paraskevi F. et al.
Int. J. Med. Sci. 2010, 7 
 
 
http://www.medsci.org 
94
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   M Me ed di ic ca al l   S Sc ci ie en nc ce es s   
2010; 7(2):94-100 
© Ivyspring International Publisher. All rights reserved 
Research Paper 
Factors affecting the long-term response to tacrolimus in renal transplant 
patients: Pharmacokinetic and pharmacogenetic approach 
Paraskevi F. Katsakiori1
, Eirini P. Papapetrou2, George C. Sakellaropoulos3, Dimitrios S. Goumenos4, 
George C. Nikiforidis3, Christodoulos S. Flordellis1  
1.  Department of Pharmacology, School of Medicine, University of Patras, Rion, Greece 
2.  Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center 
(MSKCC), New York, NY 10065, USA 
3.  Department of Medical Physics, School of Medicine, University of Patras, Rion, Greece  
4.  Department of Internal Medicine-Nephrology, School of Medicine, University of Patras, Rion, Greece  

 Corresponding author: Paraskevi F. Katsakiori, Department of Pharmacology, School of Medicine, University of Patras, 
26500 Rion, Greece, Tel: +30 6937 438208, Email: vkatsak@med.upatras.gr; vkatsak@yahoo.com 
Received: 2010.04.20; Accepted: 2010.05.10; Published: 2010.05.11 
Abstract 
Background: The aim of our study was to determine the impact of CYP3A5*1 and 
CYP3A5*3 on the kinetics of tacrolimus in renal transplant recipients.  
Material and methods: Forty kidney recipients were selected to participate. Maintenance 
scheme consisted of tacrolimus, a purine inhibitor and a steroid. CYP3A5 genotyping was 
performed with PCR and RFLP. Pharmacokinetic model was developed with Linear Regres-
sion and General Linear Model repeated measures approach. The impact of sex, CYP3A5*1 
allele, age at transplantation, hepatic and renal function on tacrolimus kinetics was examined.  
Results: The frequency of CYP3A5*3/*3 and CYP3A5*1/*3 genotype was 35/40 and 5/40, 
respectively. No CYP3A5*1/*1 was detected. CYP3A5*1 variant was associated with signif-
icant lower TAC dose adjusted concentration at 3, 6, 12 and 36 months after transplantation. 
Hepatic and renal function showed a significant effect on tacrolimus dose adjusted concen-
tration 3 months after transplantation (p=0.000 and 0.028, respectively). Sex did not show a 
significant impact on tacrolimus kinetics. Carriers of CYP3A5*1 allele had lower predicted 
measures for tacrolimus dose adjusted concentration and higher predicted measures for 
volume of distribution.  
Conclusion: W e  p r o v e d  t h a t  C Y P 3 A 5 * 1  c a r r i e r s  need higher tacrolimus dose than 
CYP3A5*3 homozygotes to achieve the target blood concentration. 
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Background 
Tacrolimus, a calcineurin inhibitor, remains the 
centerpiece of the maintenance treatment scheme in 
renal transplant recipients. Both its narrow therapeu-
tic index and its highly pharmacokinetic variance may 
lead to overtreatment and toxicity or insufficient 
treatment and transplant rejection, conditions that are 
usually seen in clinical practice. Thus, it is obvious 
that the optimal tacrolimus dose has to be achieved 
soon after transplantation and must be preserved 
thereafter.  
In the recent years, effort has been made to de-
termine the potential causes of inter- and in-
tra-individual variability. Except for the characteris-
tics of each individual and several environmental Int. J. Med. Sci. 2010, 7 
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factors, the role of biological factors affecting the drug 
absorption, distribution, metabolism or deletion has 
been investigated [1-9]. Till now, the most significant 
biological factors known to affect pharmacokinetics 
are the drug transporters and the metabolizing en-
zymes [7,9]. 
CYP3A, the primary subfamily of the cytoch-
rome P450 (CYP) enzymatic system, is responsible for 
the metabolism of tacrolimus [10]. Specifically; tacro-
limus is mainly metabolized by CYP3A4 and CYP3A5 
enzyme isotype. CYP3A5 polymorphisms seem to 
affect tacrolimus kinetics at a greater degree com-
pared to CYP3A4 ones and thereby, these polymor-
phisms are thought to be the best candidates for 
pharmacogenetics’ application in immunosuppresion 
[1,7,11-13]. CYP3A5 gene is expressed in a limited 
number of individuals. When it is expressed, it may 
count for the 50% of the total hepatic CYP3A protein 
[5,14].  
Macphee et al were the first to detect the effect of 
a CYP3A5 polymorphism in the distribution of tacro-
limus [11]. CYP3A5*3 (G6986A) polymorphism, lo-
cated in intron 3, has been recognized as the most 
important CYP3A5 polymorphism. The alleles A and 
G are CYP3A5*1 and CYP3A5*3, respectively. Indi-
viduals carrying at least one CYP3A5*1 allele express 
CYP3A5 protein whereas individuals homozygotes 
for CYP3A5*3 are non-expressors [15-18].  
There are grave indications that pharmacoge-
netic testing for CYP3A5 prior to transplantation im-
proves the individualization of immunosuppressive 
therapy although epigenetic factors must be taken 
into account [7]. The aim of the present study was to 
determine the impact of CYP3A5*1 and CYP3A5*3 
genotype on the kinetics of tacrolimus in renal trans-
plant recipients. The drug dose and level, the drug 
dose-adjusted level and the drug volume of distribu-
tion values are analyzed based on the presence of 
CYP3A5*1 allele, sex, age, renal and hepatic function. 
Material and Methods 
Patient population 
Forty renal transplant recipients (median age: 41 
years, range: 13-69), who attended the Outpatient 
Clinic of Nephrology and treated with TAC as the 
primary immunosuppressant, were selected to par-
ticipate in the study. The protocol was approved by 
the Institution Ethics Committee of our hospital and 
informed consent was obtained from all subjects. 
Maintenance treatment scheme consisted of a 
combination of a calcineurin inhibitor (tacrolimus) 
with a purine inhibitor (mycophenolate mofetil or 
azathioprine) and a steroid (prednizolone). Tacroli-
mus was given twice a day in individually adjusted 
doses and its trough levels were measured 12 hours 
post dose.  
Identification of CYP3A5 genotype 
Five milliliter blood samples were drawn from 
each patient in a vacutainer tube containing ethy-
lene-diaminetetracetic acid. Genomic DNA was ex-
tracted from 200μl whole blood by QIAamp DNA 
Blood kit (Qiagen GmbH, Hilden) and was analyzed 
on a 0.8% agarose/Tris-borate EDTA gel with ethi-
dium bromide staining (Figure 1). 
 
 
 
 
Figure 1. a. Genomic DNA. Lane M, base pair marker (λDNA 5μgr); lanes 1-9 genomic DNA from 9 blood samples. 
Analysis on a 0.8% agarose/Tris-borate EDTA gel. b. PCR for CYP3A5. Lane M, base pair marker (λDNA 5μgr); lanes 1-3 
PCR product for CYP3A5 from 3 DNA samples. Analysis on a 2% agarose/Tris-borate EDTA gel. Figure is printed negative. 
c. RFLP for CYP3A5. Lane M, base pair marker (250-bp DNA ladder); lanes 1-10 SspI-digested PCR products from 10 PCR 
products. CYP3A5*1/*1 genotype gives 148-, 125- and 20- bp bands (lanes 1, 2, 3, 6, 7 and 9) and CYP3A5*1/*3 genotype 
gives 168-, 148-, 125- and 20- bp (lanes 4, 5, 8 and 10). CYP3A5*3/*3 genotype is not seen in this picture. The 20- bp band 
is not visible. Analysis on a 3.5% agarose/Tris-borate-EDTA gel. 
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PCR followed by RFLP was used for CYP3A5 
genotyping. PCR primers for CYP3A5 were designed 
to amplify a 293 bp fragment (forward primer: 
5’-CATCAGTTAGTAGACAGATGA-3’, reverse pri-
mer: 5’-GGTCCAAACAGGGAAGAAATA-3’) [19]. 
The 25μl PCR volume contained 2.5μl 10x PCR Buffer, 
1μl MgCl2 50mM, 1μl dNTPs 10mM, 0.5μl forward 
primer 25pmol/μl, 0.5μl reverse primer 25pmol/μl, 
0.25μl TAQ polymerase 5Units/μl, 1μl isolated DNA 
and 18.25 μl ddH20. PCR conditions were 1min at 
94οC, 40 cycles of 1min at 94οC (template denatura-
tion), 1min at 55οC (primer annealing), 1min at 72οC 
(primer extension) and finally, 7min at 72οC (final 
elongation). The PCR product was analyzed on a 2% 
agarose/Tris-borate EDTA gel with ethidium bro-
mide staining (Figure 1).  
Enzymatic digestion of PCR products was per-
formed using SspI endonouclease (New England Bi-
olabs). 25 μL PCR product was incubated for 2 hours 
at 37οC with 2μl SspI 5Units/μl and 3μl 10xBuffer. A 
3.5% agarose/Tris-borate EDTA gel with ethidium 
bromide staining was used and bands were detected 
by a short wavelength UV transilluminator (Figure 1). 
CYP3A5*1/*1 genotype gives 148-, 125- and 20- bp 
bands, CYP3A5*3/*3 genotype gives 168- and 125-bp 
bands and CYP3A5*1/*3 genotype gives 168-, 148-, 
125- and 20- bp [19]. 
Statistical analysis 
Tacrolimus kinetics were estimated with the use 
of tacrolimus daily dose, concentration, dose adjusted 
concentration and volume of distribution. Transplant 
recipients weight (kgr) and daily dose (mgr/day) of 
TAC in 14 days, 1, 3, 6, 12, 24 and 36 months were 
recorded so that dose per weight (mgr/kgr/day) 
could be calculated. The tacrolimus dose adjusted 
concentration (concentration/dose ratio) and tacro-
limus volume of distribution (dose/concentration 
ratio) were calculated. Statistical analysis was per-
formed with the use of PASW Statistics 17.0 (SPSS Inc, 
Chicago, IL, USA). Pharmacokinetic parameters were 
firstly modeled with the use of Linear Regression 
(LR). The results were compared to General Linear 
Model (GLM) repeated measures results.  
LR predicts the dependent variable value based 
on the values of at least one independent variable. It 
assumes that the model depends linearly on the un-
known parameters and the conditional mean of Y 
variable given the value of X is an affine function of X. 
In GLM repeated measures approach, the dependent 
variable is measured at multiple times (n) and it is 
represented by n variables (within-subjects factors). 
Categorical factors are used to divide study popula-
tion into subgroups (between-subjects factors) and 
continuous variables are used as control variables 
(covariates). Taking into account that linear relation-
ships, normal distribution of the dependent variables 
and fixed effects exist, the effects of between- and 
within-subjects factors as well as the interaction be-
tween factors and covariates and its effects are ana-
lyzed. 
The difference between LR and GLM repeated 
measures analysis is that LR does not take into ac-
count the sequel of the data and it encounters them as 
derived from different patients. Thus, GLM repeated 
measures approach seems to be a more accurate me-
thodology for the analysis of such data but it is more 
demanding in the quantity of available data.  
In the LR analysis, the kinetic parameters were 
modeled based on sex, presence of CYP3A5*1 allele, 
age at transplantation (<40 versus ≥40 years old), he-
patic (AST≤40U/ml and ALT≤35U/ml versus 
AST>40U/ml and/or ALT>35U/ml) and renal (se-
rum creatinine ≤1.4mgr/dl versus >1.5mgr/dl) func-
tion. In the GLM repeated measures approach, a mul-
tivariate model was developed. Sex and genotype 
were used to define the subgroups of our patient 
population whilst the age at transplantation served as 
a covariate. The threshold of statistical significance 
was set at 5% (a=0.05).  
Results 
The characteristics of the study population are 
shown in Table 1. The frequency of CYP3A5*3/*3 
genotype was 87.5% (35/40) whereas the frequency of 
the CYP3A5*1/*3 genotype was 12.5% (5/40). No 
individual homozygote for CYP3A5*1 was detected. 
Patients’ renal and hepatic function as well as tacro-
limus trough concentration are presented in Table 2.  
According to LR statistical approach, the pres-
ence of CYP3A5*1 variant was associated with lower 
tacrolimus dose adjusted concentration at 3, 6, 12 and 
36 months after transplantation (Figure 2). Hepatic 
and renal function showed a statistically significant 
effect on tacrolimus dose adjusted concentration at 3 
months after transplantation (p<0.001 and 0.028, re-
spectively). There was no evidence that gender had a 
significant impact on tacrolimus kinetic parameters. 
The findings were confirmed with the use of 
GLM repeated measures approach. As seen in Figure 
3, carriers of CYP3A5*1 allele show lower predicted 
measures for tacrolimus dose adjusted concentration 
and higher predicted measures for tacrolimus volume 
of distribution. With GLM approach, the effect of 
timepoint, meaning the time after transplantation, on 
tacrolimus kinetic parameters was significant 
(p<0.001).  
 Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
97
 
 
 
 
 
 
Figure 2. Genotype effect on tacrolimus dose adjusted concentration: A linear regression model. (a. 3 months, b. 6 months, 
c. 12 months and d. 36 months after transplantation). Int. J. Med. Sci. 2010, 7 
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Figure 3. Genotype effect on tacrolimus dose adjusted concentration (a) and volume of distribution (b): A GLM repeated 
measures approach. 
 
 
 
 
 
Table 1. Demographic characteristics of patient popula-
tion (age is expressed as median value/25% quartile-75% 
quartile). 
Demographic characteristic  Number 
Gender (female/male) 13/27 
Age (years, median/range) 41/35-54 
Age for females (years) 42/37-53 
Age for males (years) 41/35-54 
Transplantation number (first/second) 28/12 
Place of transplantation (our centre/elsewhere) 36/4 
Cadaver transplantation 34 
Age at the onset of the chronic renal deficiency (years)  38/24-50 
Age at the onset of the chronic renal deficiency for 
females (years) 
36/29-49 
Age at the onset of the chronic renal deficiency for 
males (years) 
38/23-50 
Primary kidney disease   
Unknown 14 
Glomerulonephritis 9 
Cystoureteral reflux  4 
Polycystic kidney disease  3 
Diabetic nephropathy 2  
Alport syndrome 1 
Eclampsia 1 
Antiphospholipidic syndrome (Systemic lupus ery-
thematosus) 
1 
Nephrolithiasis 3 
Nephrosclerosis 1 
Nephronophthisis 1 
 
Table 2. Patients’ renal and hepatic function, and tacroli-
mus trough levels at 14 days, 1, 3, 6, 12, 24 and 36 months 
after transplantation. Values are expressed as median (25% 
quartile-75% quartile). 
Timepoint  AST (U/ml)  ALT 
(U/ml) 
Cr (mgr/dl)  Trough level 
(ngr/ml) 
14 days  15 (11-31)  27 (17-59) 1.7  (1.3-2.7) 11 (8.1-12.3) 
1 month  13 (11-17)  24 (16-34) 1.8  (1.3-2.3) 10.7  (9.2-13) 
3 months  16 (12-23)  20 (14-29) 1.6  (1.2-2.1) 10.4  (9.2-12.1) 
6 months  13 (17-21)  16 (13-22) 1.6  (1.3-2.1) 10  (8.5-11.2) 
12 months  18 (15-23)  18 (12-24) 1.4  (1.2-2) 9.1  (7.5-10.9) 
24 months  17 (14-21)  17 (11-25) 1.4  (1.1-1.7) 7.2  (6.1-8.7) 
36 months  18 (16-22)  19 (15-23) 1.3  (1.1-1.6) 6.7  (5.2-7.9) 
 
 
Discussion 
Pharmacogenetics emerged during 1950s seek-
ing to detect the potential relation between altered 
genetic basis and behavior after drug administration. 
However, several epigenetic factors such as age, 
co-morbidity, disease seriousness, co-administrated 
drug therapies and their interactions, renal and he-
patic function, nutritional and other habbits, are often 
responsible for the intra- and inter-individual varia-
bility seen after drug administration [6,9]. For these 
reasons, therapeutic drug monitoring constitutes a 
crucial step in the administration of several drug 
agents. However, this empirical treatment algorithm Int. J. Med. Sci. 2010, 7 
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carries increased risk of side effects or insufficient 
treatment. 
Taking into account the critical clinical condition 
of renal transplant recipients and the limited number 
of renal transplants, the immunosuppressant treat-
ment scheme prescribed to renal transplant patients 
must be adjusted in a way that precludes the possi-
bility of under or over-treatment. The main drug in 
the immunosuppressant scheme that kidney reci-
pients receive is tacrolimus. Most studies seek for the 
detection of polymorphisms that are associated with 
the individual’s response to tacrolimus. However, in 
order to secure the appropriate administration of ta-
crolimus, both genetic and epigenetic factors must be 
taken into account [7,15]. For this reason, we at-
tempted to model tacrolimus kinetics based on both 
genotype and epigenetic factors.  
Disparity exists in the literature as to which 
genes and which genetic polymorphisms must be 
studied. We studied the presence of CYP3A5*1 in 40 
kidney recipients. The genotype frequencies observed 
in our study are in agreement with the study of Ar-
vanitidis et al, making us assume that our study 
sample is a representative one of the population [12]. 
Besides, the frequency of CYP3A5*3 allele in Cauca-
sian Canadians is about 93%, and 83% of Dutch Cau-
casians are CYP3A5*3 homozygotes [19,20]. We chose 
to study this specific genetic polymorphism of 
CYP3A5 metabolizing enzyme as this isotype seems 
to critically affect the metabolism of TAC and this 
polymorphism is a frequent one in Greek population 
[3,5,19-21]. Besides, CYP3A5*1 has been proposed to 
regulate both the expression of CYP3A5 and CYP3A4. 
Other CYP3A5 alleles (*5, *6, *7) show low frequency 
in Caucasian population and thus, they are regarded 
as less suitable for screening purposes [19,20].  
We failed to highlight the effect of the variants 
studied in all timepoints, probably due to the pres-
ence of several parameters affecting tacrolimus kinet-
ics. The presence of CYP3A5*1 allele does not predict 
the amount of CYP3A5 protein accurately as it can be 
affected by other factors, genetic (expression of 
m-RNA, stability of CYP3A5 protein, dual metabolic 
pathway via CYP3A4 and CYP3A5, linkage disequi-
librium with CYP3AP1 pseudogene etc) or not (drug 
interactions, environmental influences etc) 
[2,4,6,7,9,11,22,23]. Although trough concentrations of 
tacrolimus were corrected for dose, differences in diet, 
habits, comorbidity or concomitant treatment 
schemes were not inspected. Due to the limited pa-
tient population, we were not able to estimate the 
impact of concomitant drug agents and comorbidities 
on the kinetics of tacrolimus. 
Till now, several studies with limited or ex-
tended patient populations have been carried out at-
tempting to clarify the influence of various factors on 
tacrolimus kinetics. However, the results remain con-
troversial with regard to pharmacokinetic and clinical 
effect of the studied parameters. Our main results are 
in alignment with the results of Zhao et al and Tsu-
chiya et al [14,17]. We found that individuals carrying 
one CYP3A5*1 allele need higher tacrolimus dose to 
achieve the target blood concentration, compared to 
CYP3A5*3 homozygotes.  
Conclusions 
We proved that CYP3A5 genotype affects indi-
viduals’ response to tacrolimus both in the early and 
late phase after renal transplantation. However, given 
that most drug effects are polygenic in nature and that 
several epigenetic factors alter tacrolimus kinetics, the 
combination of population pharmacokinet-
ic/pharmacodynamic and pharmacogenomic studies 
is deemed necessary.  
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